Total Raised

$90.34M

Investors Count

7

Deal Terms

6

Funding, Valuation & Revenue

9 Fundings

Elcelyx Therapeutics has raised $90.34M over 9 rounds.

Elcelyx Therapeutics's latest funding round was a Debt for $0.48M on November 7, 2018.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/7/2018

Debt

$0.48M

Undisclosed Investors

$XXM

0

FY undefined

1

10/1/2015

Series E

$XXM

$XXM

0

FY undefined

10

2/19/2015

Series D - II

$XXM

$XXM

0

FY undefined

10

2/21/2014

Series D

$XXM

$XXM

0

FY undefined

10

2/14/2013

Series C

$XXM

$XXM

0

FY undefined

10

Date

11/7/2018

10/1/2015

2/19/2015

2/21/2014

2/14/2013

Round

Debt

Series E

Series D - II

Series D

Series C

Amount

$0.48M

$XXM

$XXM

$XXM

$XXM

Investors

Undisclosed Investors

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

10

10

10

Start free trial
New call-to-action

Elcelyx Therapeutics Deal Terms

6 Deal Terms

Elcelyx Therapeutics's deal structure is available for 6 funding rounds, including their Series E from October 01, 2015.

Round

Series E

Series D - II

Series C

Series B - II

Series B

Funding Date

$XXM

$XXM

$XXM

$XXM

$XXM

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$XXM

$XXM

$XXM

$XXM

$XXM

Shares Authorized

Issuance Price

$XXM

$XXM

$XXM

$XXM

$XXM

Dividend Rate

$XXM

$XXM

$XXM

$XXM

$XXM

Liquidation Preferences

$XXM

$XXM

$XXM

$XXM

$XXM

Liquidation Price

Participation

Conversion Price

Anti Dilution

$XXM

$XXM

$XXM

$XXM

$XXM

General Voting

$XXM

$XXM

$XXM

$XXM

$XXM

Board Voting

$XXM

$XXM

$XXM

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series E

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series D - II

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series C

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series B - II

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series B

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Elcelyx Therapeutics Investors

7 Investors

Elcelyx Therapeutics has 7 investors. Kleiner Perkins invested in Elcelyx Therapeutics's Series E funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

5/16/2011

10/1/2015

6
Series B, Series B - II (2012), Series C (2013), Series D (2014), Series D - II (2015), Series E (2015)

Venture Capital

California

00/00/0000

00/00/0000

GSM Fund

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Morgenthaler Ventures

Subscribe to see more

Venture Capital

California

00/00/0000

00/00/0000

Clough Global

Subscribe to see more

Asset/Investment Management

Colorado

00/00/0000

00/00/0000

Sailing Capital

Subscribe to see more

Subscribe to see more

Private Equity

China

First funding

5/16/2011

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

10/1/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

GSM Fund

Morgenthaler Ventures

Clough Global

Sailing Capital

Rounds

6
Series B, Series B - II (2012), Series C (2013), Series D (2014), Series D - II (2015), Series E (2015)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Type

Venture Capital

Venture Capital

Venture Capital

Asset/Investment Management

Private Equity

Location

California

California

California

Colorado

China

New call-to-action

Compare Elcelyx Therapeutics to Competitors

Biolog Logo
Biolog

Biolog focuses on microbial phenotypic characterization and polyphasic identification within the biotechnology sector. The company provides methods for the characterization of microbial and mammalian cells and the identification of various bacteria, yeast, and fungi species. It was founded in 1984 and is based in Hayward, California.

M
MI Research

MI Research, Inc. specializes in Biotech instrumentation with excellent visualization capabilities in the area of protein crystal growth and blood viscosity measurements. MI aims to offer fluorescence base protein crystallization prescreening service and biotech instruments like blood viscometers. MI's expertise is in optics and biochemistry.

Bioskills srl Logo
Bioskills srl

BioSkills is a service company founded to provide its customers with basic and advanced skills in life science and biotech area. BioSkills achieves its primary objectives by developing original formation initiatives in order to spread relevant knowledge base.

M
Martin-Protean

Martin-Protean focuses on determining the three-dimensional structure of proteins and analyzing protein interactions in the biotechnology and pharmaceutical sectors. The company provides services such as discovering protein-protein interfaces, drug-binding sites, and quantifying hormones like oxytocin in biological samples using mass spectrometry. It is based in Chicago, Illinois.

G
Greenovation Biotech

greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins

Oligomerix Logo
Oligomerix

Oligomerix operates as a clinical-stage biotechnology company involved in the development of therapeutics for neurodegenerative diseases. The company provides oral, small-molecule drugs that inhibit tau protein self-association, addressing conditions such as Alzheimer's disease and rare tauopathies. Oligomerix targets the healthcare sector focusing on neurodegenerative disorders. It was founded in 2006 and is based in the Bronx, New York.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.